Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd has seen a positive shift in revenue estimates, particularly for IMVT-1402 in Graves' Disease, following successful updates from recent meetings. The company’s drug candidate Brepocitinib is demonstrating a significant advancement in dosing convenience over existing therapies, which positions it favorably in the marketplace and aligns with the growing investor confidence in its clinical success. Additionally, the promising results from the Phase 3 VALOR study for Brepocitinib underline its broad efficacy in treating moderate-to-severe dermatomyositis, enhancing Roivant's overall growth outlook and positioning it well against increasing competition in the biopharmaceutical space.

Bears say

Roivant Sciences faces significant challenges stemming from the failure of multiple drug candidates, including IMVT-1402 and brepocitinib, in clinical trials, which raises concerns about the viability of its pipeline and future revenue growth. Additionally, the risks associated with off-target effects from its drug mechanisms, as highlighted by key opinion leaders, suggest potential efficacy and safety issues that could hinder regulatory approvals. These setbacks, combined with ongoing unmet medical needs in the conditions they aim to treat, contribute to a pessimistic outlook on the company's financial health and stock performance.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.